Evigrade
DrugsCosmetic ingredientsCalculatorsInteractionsEvigrade SkinEvigrade Meds ↗
ConditionsJournalMethodologyPro for practitioners
ESRU

Denosumab

AEMPS

Biologic – RANKL inhibitor

ATC code: M05BX04

Brand names: Prolia, Xgeva, Acvybra

Updated · Methodology

Indications

A

Postmenopausal osteoporosis

Second line

Second-line for postmenopausal osteoporosis with high fracture risk after bisphosphonate failure or intolerance per AACE/ACE 2020 and SEIOMM 2024. Dose 60 mg subcutaneously every 6 months. FREEDOM showed 68% reduction in vertebral fracture risk and 40% in hip fracture. After discontinuation, switch to a bisphosphonate to prevent rebound (multiple vertebral fracture risk within 6–18 months of stopping).

Sources

  1. AEMPS: Ficha técnica de Denosumab (2024)
  2. N Engl J Med: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. (2009)
  3. BMJ: Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials. (2023)

ICD-10: M81.0 · ICD-11: FB83.11

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

F

Anti-aging and longevity

Not recommended

Denosumab is a monoclonal antibody against RANKL. It is prescribed for osteoporosis with high fracture risk (especially in postmenopausal women and men with prostate cancer on androgen deprivation therapy) and for prevention of skeletal events in bone metastases (NOGG 2021, AACE 2020). In anti-aging circles, denosumab is promoted as a biological for anti-aging of bones in healthy postmenopausal women without confirmed osteoporosis. In people without confirmed osteoporosis, no clinical studies of prophylactic use exist. The drug has serious risks: osteonecrosis of the jaw (especially after dental procedures), atypical femoral fractures, hypocalcemia, severe infections, and on discontinuation a risk of multiple vertebral fractures (requires immediate transition to a bisphosphonate). If denosumab was prescribed without confirmed osteoporosis, consider seeking a second opinion.

Sources

  1. AEMPS: Ficha técnica de Denosumab (2024)
  2. Cochrane: Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (2012)
How to read tiers A–F
  • AStrong evidence – first or second line in international guidelines
  • BRecommended in selected cases
  • CStudy data contradict each other
  • DBenefit not proven, no documented harm
  • FDocumented harm, or risk without benefit

Mechanism of action

A fully human IgG2 monoclonal antibody binding RANKL (receptor activator of NF-κB ligand). Blocks RANKL interaction with RANK on osteoclasts and precursors – suppresses osteoclast formation, activation, and survival. More pronounced bone resorption reduction than bisphosphonates. Unlike bisphosphonates, no bone accumulation – effect fully reverses within 6 months of discontinuation, leading to rebound (rapid resumption of bone resorption and risk of multiple vertebral fractures).

Safety

Contraindications

  • Denosumab hypersensitivity
  • Hypocalcemia
  • Pregnancy – with caution
  • Lactation
  • Age under 18

Serious adverse effects

  • Severe hypocalcemia (especially in CKD and vitamin D deficiency)
  • Osteonecrosis of the jaw (higher risk around dental procedures)
  • Atypical femoral fracture
  • Multiple vertebral fractures after discontinuation (rebound phenomenon)
  • Serious infections (cellulitis, endocarditis)
  • Allergic reactions

Common adverse effects

  • Musculoskeletal pain
  • Hypercholesterolemia
  • Urinary tract infections
  • Back pain
  • Injection site reactions

Pregnancy: can you take Denosumab?

Animal studies show embryo-fetal defects. Not used during planned pregnancy or in pregnancy.

Breastfeeding: can you take Denosumab?

No data. Not used during lactation.

Calculate RIDFull profile on NIH LactMed ↗

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Practical notes

Common myths

Myth: «denosumab can be stopped any time like a bisphosphonate – effect lasts years.» Fact: unlike bisphosphonates, denosumab does not deposit in bone. After discontinuation the antiresorptive effect fully disappears in 6 months, causing a sharp increase in bone resorption (rebound phenomenon) and risk of multiple vertebral fractures (5–10 simultaneous fractures described in the literature). Per AACE 2024 and SEIOMM 2024, post-denosumab transition to a bisphosphonate (zoledronate 5 mg IV or oral alendronate) is mandatory within 6 months of the last dose.
Label mentions2 mentions

Verbatim lines from the interaction sections, in the language of the label

From this drug’s label

  • Moderateantineoplásicosclass named in the label
    «Osteonecrosis mandibular (ONM): tratamientos concomitantes: corticosteroides, quimioterapia, inhibidores de la angiogénesis, radioterapia de cabeza y cuello.»

    AEMPS, section 4.4 · Open on CIMA

  • Moderatecorticosteroidesclass named in the label
    «Hipocalcemia: El tratamiento concomitante con glucocorticoides es un factor de riesgo de hipocalcemia adicional.»

    AEMPS, section 4.4 · Open on CIMA

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Summary of a multi-drug list →

Medicine list: everything you take in one place →

Frequently asked

What is Denosumab used for?

Denosumab is evaluated for the following indications with varying evidence strength: Postmenopausal osteoporosis (evidence tier A), Anti-aging and longevity (evidence tier F). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Denosumab?

Common side effects of Denosumab (≥ 1 in 100): Musculoskeletal pain, Hypercholesterolemia, Urinary tract infections, Back pain, Injection site reactions. See the Safety section for uncommon and serious reactions.

Is Denosumab safe during pregnancy?

Animal studies show embryo-fetal defects. Not used during planned pregnancy or in pregnancy.

Is Denosumab compatible with breastfeeding?

No data. Not used during lactation.

Who should not take Denosumab?

Denosumab is contraindicated in: Denosumab hypersensitivity; Hypocalcemia; Pregnancy – with caution; Lactation; Age under 18. Full list in the Safety section.

Official sources

Direct links to regulator labels. Open in a new tab.

Other drugs in this group

Alendronic acid, Risedronic acid